The Journal of Alzheimer's Disease published an article with new analysis that affirms the effectiveness of Prana Biotechnology Ltd.'s (Nasdaq: PRAN) Alzheimer's treatment candidate PBT2 sending the stock price soaring $1.06 to $2.41.
New Article Affirms Prana's Alzheimer's Treatment
April 19, 2010 at 17:16 PM EDT
